Publications

Dendritic cell vaccines

Subklewe M., Geiger C., Lichtenegger F.,  Javorovic M., Kvalheim G., Schendel D.J., Bigalke I. 2014. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunology. 10.1007/s00262-014-1600-5

Download PDF

Lichtenegger, F. S., Mueller, K., Otte, B., Beck, B., Hiddemann, W.,  Schendel, D. J. and M. Subklewe. 2012. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One. 7(9): e44266.

Further information

Spranger, S., Frankenberger, B. and D. J. Schendel. 2012. NOD/scid IL-2Rgnull mice: a pre-clinical model system to evaluate human dendritic cell-based vaccine strategies in vivo.  J Transl. Med. 10(1): 30. [Epub ahead of print]

Further information

Frankenberger, B. and D.J. Schendel. 2012. Third generation dendritic cell vaccines for tumor immunotherapy. Eur. J. Cell Biol. 91(1): 53-58 [Epub 2011 Mar 25]

Further information

Beck, B., Dörfel, D., Lichtenegger, F.S., Geiger, C., Lindner, L., Merk, M., Schendel, D.J., and M. Subklewe. 2011. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9:151 [Epub. Sep. 13]

Further information

Bürdek M., Spranger S., Wilde S., Frankenberger B., Schendel D.J. and C. Geiger. 2010 Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. J. Transl. Med. 8:90.

Further information

Spranger, S., Javorovic, M., Bürdek, M., Wilde, S., Mosetter, B., Tippmer, S., Bigalke, I., Geiger, C., Schendel, D.J. and B. Frankenberger. 2010. Generation of T helper-1 polarizing dendritic cells using the Toll-like receptor 7/8 agonist CL075. J. Immunol. 185(1): 738-747. 

Further information

Javorovic, M., Wilde, S., Zobywalski, A., Noessner, E., Lennerz, V., Wölfel, T., and D.J. Schendel. 2008. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J. Immunother 31(1): 52-62. 

Further information

Zobywalski, A., Javorovic, M., Frankenberger, B., Pohla, H., Kremmer, E., Bigalke, I. and D.J. Schendel. 2007. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl Med. 5:18 (highly accessed).

Further information

T cell receptor (TCR)-modified T cells for adoptive T cell therapy

Obenaus, M., Leitão, C., Leisegang, M., Chen, X., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D.J. and Blankenstein, T. 2015. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nature Biotechnology 33, 402–407 (2015).

Further information

Schendel, D.J. and P.D. Greenberg. 2014. The ABC’s of T cell receptor gene therapy. In: Cancer Immunotherapy Meets Oncology (Britten, C.M., Kreiter, S., Diken, M., Rammensee, H.-G., Eds). Pp. 117-126. Springer International Publishing, Switzerland, Heidelberg, Dordrecht, London, New York, 25.05.2014. 

Further information

Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D, Uckert, W., Blankenstein T., Kyewski, B. 2014. Mis-initiation of MART-1 transcription in the thymus and biased TCR usage can explain the high frequency of peripheral MART-1 specific T cells. Eur J Immunol. 2014 May 20 [Epub ahead of print].

Further information

Schendel, D.J. and Frankenberger, B. 2013. Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity. Oncoimmunology. 2013 Jan 1; 2(1):e22410.

Further information

Morgan, R. A., Chinnasamy, N.,  Abate-Daga, D.,  Gross, A., Robbins, P. F.,  Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., Phan, G., Hughes, M. S.,  Kammula, U. S., Miller, A., Hessman, C., Stewart, A., Restifo, R., Quezado, M. M. (+ other members of Pathology staff), Nath, A., Wang, D., Bielekova, B., Wuest, S., Nirmala, A., (+ others, NIMH deep sequencing group), Schendel, D. J., Wilde, S., Mosetter, B., Laurencot, C. and Rosenberg, S. A. 2013. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36(2):133-151.

Further information

Wilde, S. and D.J., Schendel. 2012. High-quality and high-avidity T cell clones specific for tumor-targeted antigens and how to find them. Oncoimmunology. 1(9):1643-1644.

Further information

Wilde, S., Sommermeyer, D., Leisegang, M., Frankenberger, B., Mosetter, B., Uckert, W. and D. J. Schendel. 2012. Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition. J Immunol. 189(2): 598-605.

Further information

Wilde, S., Geiger, C., Milosevic, S., Mosetter, B., Eichenlaub, S. and D.J. Schendel. 2012. Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure. Oncoimmunology. 1(2): 129-140.

Further information

Spranger, S., Jeremias, I., Wilde, S., Leisegang, M., Stärck, L., Mosetter, B., Uckert, W., Heemskerk, M., *Schendel, D. J. and B. *Frankenberger. 2012. T cell receptor-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. (* equal senior authors) Blood. 119(15): 3440-3449. [Epub ahead of print].

Further information

Leisegang M., Wilde S., Spranger S., Milosevic S., Frankenberger B., Uckert W. and D.J. Schendel. 2010. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J. Clin. Invest. 120 (11): 3869-3877.

Further information

Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D.H. and D.J. Schendel. 2009. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity. Blood 114(10): 2131-2139.

Further information

Becker, C., Pohla, H., Frankenberger, B., Schüler, T., Assenmacher, M., Schendel, D.J. and Blankenstein, T. 2001. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med.; 7 (10):1159–1162.

Further information